On this page
Ebglyss
lebrikizumab-lbkz
351(a) Standalone BLA
Overview
Source: Purple BookProprietary name
Ebglyss
Proper name
lebrikizumab-lbkz
Licence type
351(a)
BLA number
761306
Applicant
Eli Lilly and Company
Center
CDER
Presentations
2
First licensure
—
Presentations
Source: Purple Book| Strength | Dosage form | Route | Presentation | Status | Licensed |
|---|---|---|---|---|---|
| 250MG/2ML | Injection | Subcutaneous | Autoinjector | Rx | September 13, 2024 |
| 250MG/2ML | Injection | Subcutaneous | Pre-Filled Syringe | Rx | September 13, 2024 |
Sources for this page
| Purple Book | FDA | Licence type, presentations, reference product, exclusivity |